Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Q3 2024 Earnings Call Transcript October 31, 2024 Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...

Celebrations may be in order for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The ...

Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with ...

Shares of Viking Therapeutics (NASDAQ: VKTX) have soared nearly 25% in the past month, all thanks to progress with its investigational obesity and non-alcoholic steatohepatitis (NASH) candidates ...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has reported its financial and operational achievements for the third quarter ...

Anavex announced new data from their phase 2b/3 Alzheimer's trial, which was presented at the CTAD 2024 conference. Read why ...

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...

Viking (VKTX) stock fell 13% Monday afternoon after jumping 9% earlier in the day amid concerns the company might face production problems for its obesity drug candidate VK2735.